Barbara Pender

3.2k total citations · 1 hit paper
9 papers, 885 citations indexed

About

Barbara Pender is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Barbara Pender has authored 9 papers receiving a total of 885 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pathology and Forensic Medicine and 3 papers in Immunology. Recurrent topics in Barbara Pender's work include CAR-T cell therapy research (6 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Barbara Pender is often cited by papers focused on CAR-T cell therapy research (6 papers), Lymphoma Diagnosis and Treatment (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Barbara Pender collaborates with scholars based in United States. Barbara Pender's co-authors include David G. Maloney, Stanley R. Riddell, Colette Chaney, Shelly Heimfeld, Carolina Berger, Cameron J. Turtle, Laïla‐Aïcha Hanafi, Brent L. Wood, Xueyan Chen and Sindhu Cherian and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Barbara Pender

8 papers receiving 871 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells

2016 741 citations Cameron J. Turtle, Laïla‐Aïcha Hanafi et al. Science Translational Medicine profile →

Peers

Barbara Pender

ONCOL

GENET

MB

BE

IMMUN

Jeff Aycock United States

Brandon Ballard United States

Simon Thomas United Kingdom

Claudia Heuser Germany

Lori McIntyre United States

Anne Silva-Benedict United States

Stefanie Lesch Germany

Aruna Mahendravada United States

Hannah Brakke United States

ChingLam W. Wong United States

Jeff Aycock United States

Barbara Pender

589 ×0.7

ONCOL

170 ×0.6

GENET

155 ×0.6

MB

142 ×0.6

BE

144 ×0.7

IMMUN

Citations per year, relative to Barbara Pender Barbara Pender (= 1×) peers Jeff Aycock

Countries citing papers authored by Barbara Pender

Since Specialization

Citations

This map shows the geographic impact of Barbara Pender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Pender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Pender more than expected).

Fields of papers citing papers by Barbara Pender

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Pender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Pender. The network helps show where Barbara Pender may publish in the future.

Co-authorship network of co-authors of Barbara Pender

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Pender. A scholar is included among the top collaborators of Barbara Pender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Pender. Barbara Pender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Huang, Jennifer J., Emily C. Liang, Andrew J. Portuguese, et al.. (2024). Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.. Journal of Clinical Oncology. 42(16_suppl). 7034–7034. 2 indexed citations

2.

Press, Oliver W., Philip Olsen, Sang Yun Lee, et al.. (2016). Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab. Cancer Immunology Research. 4(6). 509–519. 22 indexed citations

3.

Turtle, Cameron J., Laïla‐Aïcha Hanafi, Carolina Berger, et al.. (2016). Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor–modified T cells. Science Translational Medicine. 8(355). 355ra116–355ra116. 741 indexed citations breakdown →

4.

Turtle, Cameron J., Carolina Berger, Daniel Sommermeyer, et al.. (2015). Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. Blood. 126(23). 184–184. 59 indexed citations

5.

Shadman, Mazyar, Ajay K. Gopal, Pamela S. Becker, et al.. (2015). Radioimmunotherapy consolidation using ¹³¹I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission. Leukemia & lymphoma. 57(3). 572–576. 4 indexed citations

6.

Turtle, Cameron J., Carolina Berger, Daniel Sommermeyer, et al.. (2015). Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.. Journal of Clinical Oncology. 33(15_suppl). 3006–3006. 13 indexed citations

7.

Turtle, Cameron J., Laïla‐Aïcha Hanafi, Carolina Berger, et al.. (2015). Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. Blood. 126(23). 3773–3773. 42 indexed citations

8.

Maloney, David G., Barbara Pender, Erin L. McCarthy, & Daniel P. Gold. (2007). FCgamma Receptor Polymorphisms Do Not Influence the Outcome of Treatment with Rituximab Followed by Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH).. Blood. 110(11). 3416–3416. 1 indexed citations

9.

Pender, Barbara. (1957). POLYCYSTIC DISEASE OF THE KIDNEYS. The Lancet. 270(7003). 993–993. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact